Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

Tucker Carlson's gaunt appearance sparks Ozempic rumours as weight-loss drugs become mainstream. Explore the latest ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

Ro CEO Zach Reitano joins ‘Mornings with Maria’ to discuss the launch of the Wegovy oral pill, the future of telehealth and ...

Through Shed’s GLP-1 Weight-Loss Programs, eligible members can now access Wegovy® in both oral and injectable formats, backed by ongoing support and personalized care. In addition to Wegovy®, Shed ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Friendly” labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and ...

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential ​risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...